News
Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is indicated. The phase III BE SURE clinical trial focused on comparing the efficacy and safety of bimekizumab and the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab, which currently serves as one of the mainstays of systemic therapy.
How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?
In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing…
Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer
In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the…
Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease
Are you applying the optimal approach to the treatment of chronic venous disease? What do the new…
Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early…
Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect…
Current Findings on Progressive Fibrosis in Interstitial Lung Disease
Leading pulmonologists around the world recently published the first of a series of three review…
Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The…
Current Treatment Options for Refractory/Relapsed CLL
How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review…
New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference…
Conferences
News from the world of medicine
All conferences
Popular this week
- Where did COVID come from? Are infected animals or a lab leak to blame for the pandemic?
- Target blood pressure values in heart failure
- BENIGN DERMATOSIS OF PENIS
- New Algorithm to Enhance Prediction of Cardiovascular Disease Risk
- Hypercalcemia may be the first sign of multiple myeloma, but not only that